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http:WHAT THIS PAPER ADDS?
End-stage renal disease is a major and growing healthcare problem associated with substantial costs. To facilitate
adequate haemodialysis therapy, a reliable vascular access is mandatory and can be provided by creation of
either an autologous arteriovenous ﬁstula (AVF) or a prosthetic arteriovenous graft (AVG). The implementation
of an all-autologous ﬁstula policy to maximise the use of AVF over AVG has been advocated because AVF may
have the best long-term patency, fewer complications and require less interventions once fully maturated
Although the implementation of preoperative ultrasonography examination for vessel assessment reduces the
number of early AVF failure by improved selection of the most suitable vessels and site for AVF creation, short-
and long-term AVF and AVG dysfunction is still a major healthcare problem with substantial costs for revision
and hospitalisation. Therefore, it is of interest to compare both types of access in terms of workload and costs.Background: The use of an arteriovenous ﬁstula (AVF) for haemodialysis treatment may be associated with a high
early failure rate, but usually good long-term patency, while using an arteriovenous graft (AVG) yields a lower
early failure rate with worse long-term patency. The aim of this study was to calculate and compare the costs and
outcome of AVF and AVG surgery in terms of early and long-term patencies.
Methods: A decision tree and a Markov model were constructed to calculate costs and performance of AVFs and
AVGs. The model was populated with a retrospective cohort of HD patients receiving their ﬁrst VA. The outcomes
were determined probabilistically with a 5-year follow-up.
Results: AVFs were usable for a mean (95% CI) of 28.5 months (24.6e32.5 months), while AVGs showed
a patency of 25.5 months (20.0e31.2 months). The use of AVFs was the dominant type of VA and V631 could be
saved per patient/per month patency compared to AVG use. Regardless of the willingness to pay, the use of AVFs
yielded a higher probability of being cost-effective compared to AVGs.
Conclusions: AVFs are more cost-effective than AVGs. Nonetheless, early failure rates signiﬁcantly inﬂuence AVF
performance and initiatives to reduce early failure can improve its cost-effectiveness.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Patients suffering from end-stage renal disease (ESRD)
require renal replacement therapy (RRT) with haemodialysis
(HD) as the most commonly used modality.1 HD patients
depend on a functional vascular access (VA) that is char-
acterised by a superﬁcial, low-resistance, high-ﬂow conduit
that allows for repetitive cannulation of the blood stream.To access continuing medical education questions on this paper,
go to www.vasculareducation.com and click on ‘CME’
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//dx.doi.org/10.1016/j.ejvs.2012.10.012Since its ﬁrst application,2 the arteriovenous ﬁstula (AVF),
characterised by using only autologous vessels for the
anastomosis, has been the preferred method for estab-
lishing a suitable VA.3,4 Given the relatively low risk of long-
term complications and better long-term patency compared
to other VA types, the AVF preference has been subse-
quently implemented in clinical guidelines.5,6 Despite these
clear long-term advantages, studies do show that AVFs are
susceptible to early failure and have a 20e60% chance of
not providing enough ﬂow enhancement to facilitate sufﬁ-
cient dialysis.7e9
In case autologous vessels are either not suitable or no
longer available for ﬁstula creation, prosthetic graft material
can be used for as an alternative for VA.10,11 These arte-
riovenous grafts (AVGs) show low early failure rates and
J.J.P.M. Leermakers et al. 85allow for early cannulation.12 However, AVGs are associated
with a limited survival period, show more episodes of
bacteremia, and result in more thrombotic complications
compared to AVFs.13
VA-related complications are the cause of up to 15% of
all hospitalisations and are associated with substantial
costs.14 Bacteremia-related hospitalisation in patients with
a central vein catheter (CVC) are estimated at $23 000 per
hospitalisation in the US,15 accumulating to $2.0 billion in
incident CVC patients.16 Radiological interventions for
access malfunction can add up to over $18 000 per patient-
year at risk.17 Therefore, identiﬁcation of the VA-type with
the lowest complication rates would provide important
information regarding both costs and functionality.
Although AVFs is still preferred to AVGs given its better
long-term outcomes, more recent studies argue that this
preference might be overestimated.18e21 It has been
postulated that publications regarding the functional
outcome of AVFs have focussed on patencies after the
initial maturation of both VAs, thereby disregarding the high
early failure of AVFs.18 These ﬁndings raise issues regarding
both cost and effects of AVF and AVG and suggest that
unconditional favouring of AVF may not be the preferred
policy.18e20 In order to investigate which VA type would be
more cost-effective, the aim of this study was to calculate
and compare the costs and effects of primary AVF and AVG
surgery from a hospital perspective.MATERIALS AND METHODS
A decision model has been created using a combination of
a decision tree and a Markov model. The time frame was set
at 62 monthse2 months for the short-term decision tree
and 60 months for the long-term Markov model e which is
in line with the average ESRD-patient life expectancy.22 The
main outcome measures assessing functionality have been
the time (in months) a VA was usable and the incremental
cost-effectiveness ratio (ICER; difference in costs divided by
difference in effects of AVF and AVG).
The current study was approved by the medical ethical
committee of the Maastricht University Medical Center.Decision tree
In the base-case model, the initial choice of VA type (AVF or
AVG) was made and was assumed to be equally distributed
to allow comparison between treatments (50% of patients
receiving AVF and 50% of patients receiving AVG). The time
frame of the decision tree has been set at 2 months and
was assumed to be sufﬁcient for determining functionality.
The base-case study considered three chance nodes
resulting in a total of 12 possible scenarios: six for AVF and
six for AVG (Fig. 1A). These scenarios included functional VA
within 2 months of surgery, death (possible after each
chance node), successful intervention after early failure and
unsuccessful intervention after early failure. Therefore,
these six scenarios per VA type represented three possible
health state outcomes at decision tree end, being eitherfunctional, nonfunctional with requirement of a change of
modality or death.
Markov model
After the initial maturation phase, patients entered the
Markov model in the health state corresponding to the
decision tree outcome (i.e., functional, change of modality
or death). The model distinguished four mutually exclusive
health states and models repetitive, monthly cycles by
allowing patients to transition to a different health state at
the end of each cycle (Fig. 1B). Patients entering the Markov
model with a functional VA had a risk of losing usability,
necessitating a radiological or surgical intervention. To
ensure continuous HD therapy, patients transitioning to
‘shunt failure’ were assumed to receive a temporary CVC.
However, if VA failure was permanent, a change in dialysis
modality or referral for completely new access, thereby
transitioning to ‘change of modality’ health state, was
mandatory. This latter state was considered to bear no costs
or transitions since these could not be attributed to the
initial abandoned VA type (i.e., costs and effects of a second
VA after abandonment of the initial VA did not contribute
to initial VA performance). Patients in health states ‘func-
tional’ and ‘shunt failure’ were considered susceptible to
infectious episodes. From the health state ‘death’ no tran-
sitions could occur.
Identiﬁcation of costs and effects
Identiﬁcation of cost-bearing events has been done using
European guidelines for VA.6 Surgical interventions involved
thrombectomy, revision of anastomosis, ﬂow-reducing
procedures, ligation of sidebranches, radiological assistance
using digital subtraction angiography (DSA), super-
ﬁcialisation (in AVFs) and graft extensions/bypasses (in
AVGs). For all surgical procedures, the associated hospital-
isation has been taken into account. Surgical interventions
were considered to cause 1 month loss of functionality if
successful, due to healing and adaptation, while radiological
interventions were assumed not to hamper functionality,
given its less invasive character. In some AVGs, new graft
interpositions may be possible with continuity of dialysis
treatment by cannulation of the original graft segment.
CVC-related costs have been identiﬁed as CVC placement,
CVC removal, hospitalisation and surgical consultation.
Radiological interventions were assumed to consist solely of
percutaneous transluminal angioplasty (PTA). Pre-operative
work-up, post-operative assessment of functionality and
follow-up measurements have been taken into account and
involved duplex ultrasonography (DUS) and surgical
consultation. Furthermore, infectious complications were
identiﬁed as wound infection (outpatient treatment) and
bacteremia (in-hospital treatment).
Measurement of costs and effects
In order to populate the combined decision model,
a retrospective cohort of all newly created upper extremity
VAs between 1 January 2000 and 31 December 2009 in the
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Figure 1. Decision model. (A): Decision tree for the ﬁrst two months after vascular access indication. Probabilities of pathways after each
node are given (similar to Table 2). After passing through the decision tree patients enter the Markov model in the health state corre-
sponding with the scenario at decision tree end (B). Markov model showing possible transitions at cycle end. Probabilities of these
transitions were different for AVF and AVG treatments and are shown in Table 3.
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bled. Patients with previous ipsilateral VA placement were
excluded, since prior procedures in the same extremity
could potentially alter performance.23 Within the
mentioned time frame, a total of 322 VA procedures, 230
AVFs (95 radiocephalic, 57 brachiocephalic, 78 brachioba-
silic AVF) and 92 AVGs were included. Pre-operative
demographics were collected, together with information on
peri- and postoperative complications for a period of 18months after surgery. The cohort has been used to depict
the proportion of patients in every scenario of the decision
tree as well as transition probabilities for every health state
in the Markov model. Radiological intervention rate was
established and converted to a per-month scale. Types of
surgical interventions related to VA have been identiﬁed
together with their success rate. Due to lack of information
on infectious episodes during follow-up, data regarding
infection and bacteremia were estimated using prior
Table 1. Unit-prices of cost-bearing events.
Cost type Costa
Initial surgery AVF V1195.13b
AVG V1379.23b
Duplex ultrasonography (DUS) Pressure
measurement
V80.11b
Ultrasonography V27.19b
Surgical consultation (ﬁrst) V83.33b
Surgical consultation (follow-up) V60.46b
Hospitalization (daycare) V237.91c
Hospitalization (overnight) V545.02c
Surgical interventions Re-operation V689.62b
Banding procedure V689.62b
Thrombectomy V689.62b
Ligation/excise V337.01b
Interposition V1011.02b
Superﬁcialization V1011.02b
Ligation of
sidebranches
V689.62b
Radiological procedures PTA/stenosis V578.57b
Angiography (DSA) V386.24b
Catheter related Catheter insertion V505.51b
Catheter removal V168.50b
Infection related Blood culture V12.81b
Antibiotics V4.32d
a All costs converted to 2006 euros. Sources of unit-prices indi-
cated by number.
b Internal transfer cost-pricing.
c (26).
d (25).
J.J.P.M. Leermakers et al. 87reports.24,25 Cost data have been derived from internal
transfer pricing, using the hospital information system,
complemented with reference cost prices when necessary.
Valuation and discounting
All costs were converted to 2006 euros using consumer
price index.26 The year 2006 was chosen as the baseline
year since it falls in the middle of the studied period (2000e
09). In the decision tree, costs for every scenario have been
estimated. Furthermore, the different types of surgical
procedures after early failure were weighed by occurrence
in the patient cohort, resulting in an aggregated cost price
of surgical revision: one for AVF and one for AVG. Attribu-
tion of costs in the decision tree was done by multiplying
the expected costs by the proportion of patients in each
scenario.
Similarly, in the Markov model, a monthly cost of each
health state was composed of unit prices of cost-bearing
events occurring in these states. Again, cost of surgical
intervention was established by weighing different inter-
ventions according to occurrence in the patient cohort.
Since the same amount of money has different value over
time due to interest, inﬂation and other factors, the costs
for the same intervention or treatment were considered to
increase by 4% the year after, as recorded in a 4% annual
discount rate.
Decision tree and Markov model analysis
Base-case analysis of decision tree and Markov model
simulation were performed with Excel 2003 (Microsoft
Corp., Redmond, WA, USA). The model has been made
probabilistic using the method described by Briggs et al.27
The patient cohort data were used to assess the standard
error of probability of scenarios in the decision tree as well
as transition probabilities in the Markov model. Identiﬁed
cost-bearing events were assumed to have a standard error
of 20% of the total cost price. Monte Carlo simulation with
5000 iterations has been performed to encompass both
transition uncertainty as well as cost uncertainty. Outcomes
in terms of costs and effects have been used to calculate
ICER, in this case stating the extra cost for an extra month
patency between AVF and AVG. However, it could be
argued that if one would be willing to pay a low amount for
one extra month of patency, a better patency for AVF would
not be favourable if the costs for this are very high.
Therefore, the probability of AVF being cost-effective has
been investigated at an increasing willingness to pay for
a month of patency.
Robustness of the model for input variability was
assessed by sensitivity analysis. Changes in early failure
rates of AVFs, success rates of surgical interventions of
AVGs and long-term mortality of AVGs were made in the
base case, to investigate changes in outcome.
RESULTS
Unit prices of all identiﬁed events in the decision model are
given in Table 1. Depiction of events occurring in the modelresulted in costs for every scenario of the decision tree and
health states in the Markov model.Decision tree analysis
Decision tree analysis showed that 84.8% of AVGs and
81.3% of AVFs were suitable for cannulation after 2 months.
Successful revision after early failure/non-maturation was
more common in the AVG group (50%) compared to the
AVF group (16%), resulting in a higher early failure rate in
AVFs. Short-term mortality rates after surgery, after matu-
ration and after intervention for non-maturation were
higher in patients receiving a graft (2.2%, 5.6% and 7.1%
respectively), compared to 0.4%, 2.2% and 0.0% in AVFs.
The proportion of patients ending up in the different
scenarios, together with the costs for that scenario,
revealed an expected cost at decision tree end (Table 2).
AVF surgery and maturation yielded a total expected cost of
V2178.10 and was lower than costs for revision of early
failed AVGs, being V2445.38.Markov model analysis
Markov model outcomes resulted in costs and transition
probabilities for both VA types (Table 3). The expected costs
of 1 month functionality were V84.80 for AVFs and
V120.99 for AVGs and involved costs for radiological
interventions and outpatient treatment of infection.
Furthermore, costs of 1 month failure were V1700.97 for
Table 2. Probabilities and costs of scenario’s in decision tree.
Scenario Probability (se) Cost (95% CI) Expected cost
AVF
A: Death after surgery 0.004 (0.004) V1623.66 (V1187.46eV2175.91) V7.06
B: Functional after non-maturation 0.030 (0.011) V3130.26 (V2601.58eV3733.20) V95.27
C: Change of modality after non-maturation 0.161 (0.024) V3130.26 (V2601.58eV3733.20) V503.56
D: Death after non-maturation e V2962.50 (V2437.20eV3556.97) Ve
E: Functional 0.783 (0.027) V1959.17 (V1495.51eV2508.16) V1533.27
F: Death after maturation 0.022 (0.010) V1791.42 (V1337.40eV2338.06) V38.94
Total V2178.10 (V1722.11e2702.91)
AVG
G: Death after maturation 0.054 (0.024) V1975.52 (V1484.47eV2564.72) V107.37
H: Functional 0.772 (0.044) V2143.28 (V1637.28eV2736.84) V1654.05
I: Death after non-maturation 0.011 (0.011) V4101.80 (V3446.20eV4819.59) V44.58
J: Change of modality after non-maturation 0.065 (0.026) V4246.70 (V3593.69eV4971.07) V276.96
K: Functional after non-maturation 0.076 (0.027) V4246.70 (V3593.69eV4971.07) V323.12
L: Death after surgery 0.022 (0.003) V1807.77 (V1318.08eV2387.82) V39.30
Total V2445.38 (V1889.14e3081.10)
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due to a higher incidence of surgical interventions in the
AVG group. The proportion of patients in each state over
time for both VA-types is given in Fig. 2.
Base-case analysis
Outcomes are given as expected value with their 95%
conﬁdence interval (CI). An AVF was usable for HD therapy
for 28.5 months (24.6e32.5). The cost associated with this
patency was estimated to be V7201.98 (V5972.94e
8588.11), resulting in a price per month patency of V252.26
(V210.76e298.78). Similarly, patency for grafts was esti-
mated at 25.5 months (20.0e31.2) at an average cost of
V9137.34 (V7207.04e11417.46), resulting in a price per
month patency of V358.57 (V288.30e452.82).
AVFs were usable for 3.0 months (3.7e9.8) longer with
a cost reduction of V1935.36 (V468.43e4724.84)
compared to AVGs. The calculated ICER, in this caseTable 3. Monthly transition probabilities and costs of Markov model.
Health state Expected cost (95% CI)
AVF
Functional V84.80 (V61.91eV110.81)
Failure V1700.97 (V1468.58eV1955.64)
Change of modality e
Death e
AVG
Functional V120.99 (V86.53eV160.32)
Failure V1998.71 (V1675.21eV2359.51)
Change of modality e
Death emeaning the cost saved of using an AVF over an AVG for
every extra month patency, was V631.03 per patient. This
difference, however, was not statistically signiﬁcant.
Fig. 3 shows the results of the Monte Carlo simulation on
the cost-effectiveness plane, whereby a point in the
southeast quadrant indicates in favour of AVF, a point in the
northwest quadrant in favour of AVG and both northeast
and southwest indicate a trade-off. Further investigation
revealed that at an increasing willingness to pay, the
probability of AVF surgery being more cost-effective does
not fall beneath 79%.
Sensitivity analysis
Sensitivity analysis outcomes are shown in Fig. 4. The base-
case analysis showed an AVF early failure rate of 19%.
Sensitivity analysis regarding maturation of AVF revealed
that patency outcomes would be similar for both VA types
when AVF early failure rate would increase to 30%.Transitions Probabilities (se)
Functional to failure 0.044 (0.004)
Functional to death 0.010 (0.002)
Failure to functional 0.567 (0.042)
Failure to death 0.044 (0.018)
Failure to change of modality 0.110 (0.027)
e e
e e
Functional to failure 0.057 (0.007)
Functional to death 0.011 (0.003)
Failure to functional 0.533 (0.057)
Failure to death 0.067 (0.029)
Failure to change of modality 0.120 (0.037)
e e
e e
Figure 2. Proportion of patients in every state in the Markov model over time for AVG (A) and AVF (B).
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surgical interventions for early failure has been investigated.
Thrombosed or failed AVGs were found to be salvageable in
50% of the cases. Increasing the salvage rate for failed AVGs
did not result in AVG patency becoming as high as AVF
patency, meaning that ﬁndings were robust for changes in
AVG salvage rate.
Finally, ﬁndings on AVGmortality rates with a functional VA
in the Markov model were checked for sensitivity. Monthly
mortality rates for AVF and AVG in the base case have been
estimated at 0.010 and 0.011, respectively (Table 3). Reducing
the monthly mortality rate for AVGs revealed that patency
outcomes would be similar when the mortality rate for AVG
would drop to 0.006 per month (Fig. 4).
DISCUSSION
Given the necessity for frequent HD, a VA should be char-
acterised by sustainable usability (patency) and a minimal
amount of complications (and costs). The aim of this study
was to calculate and compare the hospital costs and effects
of primary AVF and AVG surgery. Using follow-up data from
a single patient cohort to model probabilities, it was found
that, on average, the AVF is usable for a longer period of
time and yields less costs than the AVG. The average costsaved per extra month patency was V631.03 per patient in
favour of AVF surgery. Changing the success rate for inter-
ventions on AVGs did not alter ﬁndings, while monthly
mortality rate for AVGs would have to decrease to almost
half the value of AVFs to reach equivalent outcomes (0.006
vs. 0.010). However, patients receiving grafts were probably
older and had more comorbidities leading to a higher
intervention rate and mortality compared to patients with
AVFs. The outcomes showed to be sensitive to ﬂuctuations
in maturation rate of AVFs. Approximately, a 10% increase
in early failure of AVFs resulted in 3 months less patency for
AVFs, thereby reaching equivalence with AVG patency. In
this respect, an adequate preoperative vessel assessment
and decision-making before ﬁstula creation may improve
early failure rates.
To our knowledge, this is the ﬁrst study comparing cost
and effects of VA surgery based on a unique patient cohort
instead of using multiple sources from different pop-
ulations. Nonetheless, this study has some limitations. First,
it was designed as a cost-effectiveness analysis from
a hospital perspective, thereby disregarding the societal
impact. However, a clear indication of this impact can be
derived from the clinical workload associated with VA
management (i.e., a large amount of VA-related
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Figure 3. Monte Carlo simulation on the cost-effectiveness plane for AVF surgery. The x-axis indicate the difference in patency compared to
AVG surgery, while the y-axis indicate the difference in costs compared to AVG surgery. Each point indicates a possible outcome given the
uncertainty. A point in the SoutheEast quadrant indicates in favour of AVF (having a better patency at a lower cost than AVG) a point in
the NortheWest quadrant in favour of AVG (having a worse patency at a higher cost than AVG) and both NortheEast and SoutheWest
indicate a trade-off (having a worse patency at a lower cost or having a better patency at a higher cost). The dotted lines indicate the 95%
conﬁdence interval of both costs and effects.
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on society). Second, AVF and AVG surgery comprises
a whole range of different VA subtypes (e.g., at different
sites of the upper arm). Prior studies suggest that there are
signiﬁcant differences in performance of speciﬁc VA
subtypes as well.28,29 Whether outcomes would differ when
these subtypes are taken into account remains unclear.
The focus in this study on primary VA creation alone has
some implications as well. Given the early referral policy in
our centre the assumption was made that patients were not
dialysis dependent at inclusion. Although it has been argued
that AVGs can be used for dialysis as short as 2 weeks,30 this
permitted the assumption of a set maturation time of 2
months. In addition, it was believed that costs and effects of
a secondary VA procedure were not attributable to the
primary VA type. Although this allows for a clear under-
standing of primary VA performance, it can be argued that
this underestimates costs, especially in patients with early
failure. However, the endpoint chosen in this study was the
time of functionality instead of patient survival to ensure
that costs and effects were measured on similar grounds.
Although prior studies on patency mostly disregard the
maturation phase, they tend to favour AVFs over AVGs as
well.28,29 There are, however, some recent reports available
that do incorporate the period of maturation. Xue et al.19
reported a cost-utility analysis, using quality-adjusted
survival as the outcome measure. Although their analysisincluded multiple VAs per patient, they also concluded in
favour of AVF.19 Similarly, Rosas et al.20 reported a cost-
utility analysis on primary AVF or primary AVG placement.
They incorporated ﬁve annual cycles and allowed for one
complication a year; they also conclude in favour of a ﬁstula
ﬁrst strategy.20 Although both studies report a clear pref-
erence for AVFs, they both argue that the role for AVGs
should not be underestimated in patients with a high
chance of early ﬁstula failure. In line with these results is
the review by Allon et al.,18 showing higher failure rates for
AVFs compared to studies a decade ago, and suggesting
that the choice of VA type should not unconditionally be in
favour of AVF, but should consider dialysis initiation, life
expectancy, access history and chance of failure as well.18
Although the results in our study are mostly in agreement
with the ﬁndings mentioned above, the lower AVF early
failure rate found here (19% compared to rates up to 60%
(7e9)) resulted in a more pronounced preference for AVFs.
This low early failure rate may be the result of a centre
effect. All operations were performed by a single surgeon
with longstanding experience in VA surgery and the hospital
served as a referral centre for difﬁcult VA. We therefore
believe that increasing the construction of AVFs has to be
accompanied by initiatives aimed at reducing early failure
to fully beneﬁt from better long-term performance.
Considering primary VA creation, our study revealed that
AVF surgery is more cost-effective than creation of an AVG.
Patency 
equilibrium
Base case
20
24
28
32
10% 20% 30% 40%
Failure rate of AVF (%)
P
a
t
e
n
c
y
(
m
o
n
t
h
s
)
AVF
AVG
Patency 
equilibrium
Base case
20
24
28
32
0,005 0,006 0,007 0,008 0,009 0,01 0,011 0,012
Monthly mortality rate AVG
P
a
t
e
n
c
y
(
m
o
n
t
h
s
)
AVF
AVG
A
B
Figure 4. Sensitivity analysis. (A): Patency outcomes with increasing early failure rate of AVF. (B): Patency outcomes with reduced mortality
rate for AVG.
J.J.P.M. Leermakers et al. 91Even though performance and cost differences did not
reach signiﬁcance, AVFs had a higher probability of being
cost-effective than AVG, irrespective of willingness to pay.
Early failure seems to be the most inﬂuential parameter on
AVF performance, and emphasising on reducing these rates,
rather than unconditionally favour AVFs, would most likely
prove to be beneﬁcial for the workload and expenses
allocated to the ESRD patient population. In this respect
one may think of creating centres of excellence to improve
the outcome of VA surgery.
CONFLICT OF INTEREST/FUNDING
None.
REFERENCES
1 Grassmann A, Gioberge S, Moeller S, Brown G. ESRD
patients in 2004: global overview of patient numbers,treatment modalities and associated trends. Nephrol Dial
Trans 2005;20:2587.
2 Brescia MJ, Cimino JE, Appel K, Hurwich B. Chronic hemodial-
ysis using venipuncture and a surgically created arteriovenous
ﬁstula. Am J Clin Prilli 1966;45:493e6.
3 Ethier J, Mendelssohn DC, Elder SJ, Hasegawa T, Akizawa T,
Akiba T, et al. Vascular access use and outcomes: an
international perspective from the dialysis outcomes and
practice patterns study. Nephrol Dial Transplant 2008;23:
3219.
4 Meichelboeck W. End-stage renal disease (ESRD) epidemiology
- where are we going? (Abstract Vascular Access Society
congress, Istanbul, Turkey, May 5-7, 2011). J Vasc Acces
2011;12:137.
5 NKF-K/DOQI. Kidney disease outcome quality initiative (K/
DOQI): clinical practice guidelines for vascular access. In:
Foundation NK, editor. Kidney disease outcome quality initia-
tive (K/DOQI): clinical practice guidelines for vascular access.
National Kidney Foundation; 2006.
92 European Journal of Vascular and Endovascular Surgery Volume 45 Issue 1 January/20136 Tordoir JHM, Canaud B, Haage P, Konner K, Basci A, Fouque D,
et al. EBPG on vascular access. Nephrol Dial Transplant
2007;22(suppl. 2):ii88.
7 Allon M, Robbin ML. Increasing arteriovenous ﬁstulas in
hemodialysis patients: problems and solutions. Kidney Int
2002;62:1109e24.
8 Huijbregts HJT, Bots ML, Wittens CHA, Schrama YC, Moll FL,
Blankestijn PJ. Hemodialysis arteriovenous ﬁstula patency
revisited: results of a prospective, multicenter initiative. Clin J
Am Soc Nephrol 2008;3:714.
9 Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS,
Greenberg A, et al. Effect of clopidogrel on early failure of
arteriovenous ﬁstulas for hemodialysis. JAMA: J Am Med Assoc
2008;299:2164.
10 Schild AF. Maintaining vascular access: the management of
hemodialysis arteriovenous grafts. J Vasc Access 2010;11:92e
9.
11 James M, Manns B, Hemmelgarn B, Ravani P. What’s next after
ﬁstula ﬁrst: is an arteriovenous graft or central venous catheter
preferable when an arteriovenous ﬁstula is not possible? Sem
Dial 2009;22:539e44.
12 Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E,
Gillespie B, et al. Vascular access use in Europe and the United
States: results from the DOPPS. Kidney Int 2002;61:305e16.
13 Nassar GM, Ayus JC. Infectious complications of the hemodi-
alysis access. Kidney Int 2001;60(1):1e13.
14 Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF,
Berlin JA. Hemodialysis vascular access morbidity in the United
States. Kidney Int 1993;43:1091e6.
15 Ramanathan V, Chiu EJ, Thomas JT, Khan A, Dolson GM,
Darouiche RO. Healthcare costs associated with hemodialysis
catheter-related infections: a single-center experience. Infect
Control Hosp Epidemiol: Ofﬁcial J Soc Hosp Epidemiol Am
2007;28:606.
16 Allon M, Dinwiddie L, Lacson E, Latos DL, Lok CE, Steinman T,
et al. Medicare reimbursement policies and hemodialysis
vascular access outcomes: a need for change. J Am Soc Nephrol
2011;22:426.
17 Bizarro P, Coentrão L, Ribeiro C, Neto R, Pestana M. Endovas-
cular treatment of thrombosed dialysis ﬁstulae: a cumulative
cost analysis. Catheter Cardiovasc Interv 2011;77:1065e70.
18 Allon M, Lok CE. Dialysis ﬁstula or graft: the role for random-
ized clinical trials. Clin J Am Soc Nephrol 2010;5:2348.
19 Xue H, Lacson E, Wang W, Curhan GC, Brunelli SM. Choice of
vascular access among incident hemodialysis patients:a decision and cost-utility analysis. Clin J Am Soc Nephrol
2010;5:2289.
20 Rosas SE, Feldman HI. Synthetic vascular hemodialysis access
versus native arteriovenous ﬁstula: a cost-utility analysis. Ann
Surg 2012;255:181e6.
21 Tamura MK, Tan JC, O’Hare AM. Optimizing renal replacement
therapy in older adults: a framework for making individualized
decisions. Kidney Int 2012;82:261e9.
22 Renine Stichting. Statistisch jaarverslag [Statistical annual
report]. Rotterdam 2007.
23 Salman L, Alex M, Unger SW, Contreras G, Lenz O, Asif A.
Secondary Autogenous arteriovenous ﬁstulas in the "Fistula
ﬁrst" Era: results of a longterm prospective study. J Am Coll
Surgeons 2009;209:100e5.
24 Lafrance JP, Rahme E, Lelorier J, Iqbal S. Vascular access-related
infections: deﬁnitions, incidence rates, and risk factors. Am J
Kidney Dis 2008;52:982e93.
25 Commissie Farmaceutische Hulp. Farmacotherapeutisch kom-
pas. In: Medical pharmacotherapeutic education. Amstelveen:
College voor zorgverzekeringen [Dutch Health Care Insurance
Board; 2005.
26 Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding
voor kostenonderzoek, methoden en standaard kostprijzen
voor econmische evaluaties in de gezondheidszorg. In: Manual
for cost research: methods and unit-costs for economic eval-
uations in health care. Diemen: College voor zorgverzeker-
ingen, [Dutch Health Care Insurance Board; 2010.
27 Briggs A, Sculpher M, Claxton K. Decision modelling for health
economic evaluation. OUP Catal 2006:176e9.
28 Rooijens P, Burgmans J, Yo T, Hop W, De Smet A, Van Den
Dorpel M, et al. Autogenous radial-cephalic or prosthetic
brachial-antecubital forearm loop AVF in patients with
compromised vessels? A randomized, multicenter study of the
patency of primary hemodialysis access. J Vasc Surg 2005;42:
481e6.
29 Keuter XHA, De Smet AAEA, Kessels AGH, van der Sande FM,
Welten RJTJ, Tordoir JHM. A randomized multicenter study of
the outcome of brachial-basilic arteriovenous ﬁstula and
prosthetic brachial-antecubital forearm loop as vascular access
for hemodialysis. J Vasc Surg 2008;47:395e401.
30 Saran R, Dykstra DM, Pisoni RL, Akiba T, Akizawa T,
Canaud B, et al. Timing of ﬁrst cannulation and vascular
access failure in haemodialysis: an analysis of practice
patterns at dialysis facilities in the DOPPS. Nephrol Dial
Transplant 2004;19:2334.
